BR112022025653A2 - Vacina autoamplificante de rna sars-cov-2 - Google Patents
Vacina autoamplificante de rna sars-cov-2Info
- Publication number
- BR112022025653A2 BR112022025653A2 BR112022025653A BR112022025653A BR112022025653A2 BR 112022025653 A2 BR112022025653 A2 BR 112022025653A2 BR 112022025653 A BR112022025653 A BR 112022025653A BR 112022025653 A BR112022025653 A BR 112022025653A BR 112022025653 A2 BR112022025653 A2 BR 112022025653A2
- Authority
- BR
- Brazil
- Prior art keywords
- cov
- sars
- self
- vaccine
- rna self
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/08—RNA viruses
- C07K14/18—Togaviridae; Flaviviridae
- C07K14/1808—Alphaviruses or Group A arboviruses, e.g. sindbis, VEE, EEE, WEE, semliki forest virus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/577—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 tolerising response
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/20011—Coronaviridae
- C12N2770/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/36011—Togaviridae
- C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
- C12N2770/36122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/36011—Togaviridae
- C12N2770/36111—Alphavirus, e.g. Sindbis virus, VEE, EEE, WEE, Semliki
- C12N2770/36141—Use of virus, viral particle or viral elements as a vector
- C12N2770/36143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/10—Plasmid DNA
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2830/00—Vector systems having a special element relevant for transcription
- C12N2830/50—Vector systems having a special element relevant for transcription regulating RNA stability, not being an intron, e.g. poly A signal
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Virology (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Genetics & Genomics (AREA)
- Communicable Diseases (AREA)
- Microbiology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Biomedical Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Pulmonology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
VACINA AUTOAMPLIFICANTE DE RNA SARS-COV-2. A presente invenção refere-se a moléculas de RNA autorreplicantes compreendendo uma sequência que codifica proteínas não estruturais de alfavírus e uma sequência que codifica um antígeno de proteína de SARS-CoV-5 2.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP20181249 | 2020-06-19 | ||
EP20184036 | 2020-07-03 | ||
EP21170302 | 2021-04-23 | ||
PCT/EP2021/066679 WO2021255270A1 (en) | 2020-06-19 | 2021-06-18 | Self-amplifying sars-cov-2 rna vaccine |
Publications (1)
Publication Number | Publication Date |
---|---|
BR112022025653A2 true BR112022025653A2 (pt) | 2023-03-07 |
Family
ID=76532219
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR112022025653A BR112022025653A2 (pt) | 2020-06-19 | 2021-06-18 | Vacina autoamplificante de rna sars-cov-2 |
Country Status (12)
Country | Link |
---|---|
US (1) | US20230256083A1 (pt) |
EP (1) | EP4168042A1 (pt) |
JP (1) | JP2023534900A (pt) |
KR (1) | KR20230028405A (pt) |
CN (1) | CN116390752A (pt) |
AU (1) | AU2021291231A1 (pt) |
BR (1) | BR112022025653A2 (pt) |
CA (1) | CA3187290A1 (pt) |
IL (1) | IL299169A (pt) |
MX (1) | MX2022016105A (pt) |
WO (1) | WO2021255270A1 (pt) |
ZA (1) | ZA202300548B (pt) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP4355880A1 (en) * | 2021-06-17 | 2024-04-24 | Elixirgen Therapeutics, Inc. | Temperature-controllable, self-replicating rna vaccines for viral diseases |
US20230233674A1 (en) * | 2022-01-21 | 2023-07-27 | University Of Houston System | Intranasal vaccines and therapeutics for respiratory diseases |
WO2023202711A1 (zh) * | 2022-04-22 | 2023-10-26 | 仁景(苏州)生物科技有限公司 | 一种基于新型冠状病毒的mRNA疫苗 |
US20230366001A1 (en) * | 2022-05-12 | 2023-11-16 | SunVax mRNA Therapeutics Inc. | Synthetic self-amplifying mrna molecules with secretion antigen and immunomodulator |
WO2024050482A2 (en) * | 2022-08-31 | 2024-03-07 | Beth Israel Deaconess Medical Center, Inc. | Compositions and methods for treating coronavirus infection |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6451592B1 (en) | 1996-04-05 | 2002-09-17 | Chiron Corporation | Recombinant alphavirus-based vectors with reduced inhibition of cellular macromolecular synthesis |
ES2321212T3 (es) | 2004-05-18 | 2009-06-03 | Alphavax, Inc. | Vectores alfavirus derivados de tc-83, particulas y metodos antecentes de la invencion. |
US7332322B2 (en) | 2004-09-14 | 2008-02-19 | Ilya Frolov | Venezuelan equine encephalitis virus replicons with adaptive mutations in the genome and uses thereof |
WO2009046388A1 (en) * | 2007-10-03 | 2009-04-09 | United States Medical Research & Material Command | Cr-2 binding peptide p28 as molecular adjuvant for dna vaccines |
-
2021
- 2021-06-18 CA CA3187290A patent/CA3187290A1/en active Pending
- 2021-06-18 BR BR112022025653A patent/BR112022025653A2/pt unknown
- 2021-06-18 MX MX2022016105A patent/MX2022016105A/es unknown
- 2021-06-18 IL IL299169A patent/IL299169A/en unknown
- 2021-06-18 AU AU2021291231A patent/AU2021291231A1/en active Pending
- 2021-06-18 EP EP21733820.1A patent/EP4168042A1/en active Pending
- 2021-06-18 KR KR1020237001910A patent/KR20230028405A/ko unknown
- 2021-06-18 CN CN202180060847.7A patent/CN116390752A/zh active Pending
- 2021-06-18 US US18/001,912 patent/US20230256083A1/en active Pending
- 2021-06-18 WO PCT/EP2021/066679 patent/WO2021255270A1/en unknown
- 2021-06-18 JP JP2022577630A patent/JP2023534900A/ja active Pending
-
2023
- 2023-01-12 ZA ZA2023/00548A patent/ZA202300548B/en unknown
Also Published As
Publication number | Publication date |
---|---|
CA3187290A1 (en) | 2021-12-23 |
KR20230028405A (ko) | 2023-02-28 |
JP2023534900A (ja) | 2023-08-15 |
ZA202300548B (en) | 2023-09-27 |
EP4168042A1 (en) | 2023-04-26 |
IL299169A (en) | 2023-02-01 |
CN116390752A (zh) | 2023-07-04 |
MX2022016105A (es) | 2023-03-08 |
WO2021255270A1 (en) | 2021-12-23 |
US20230256083A1 (en) | 2023-08-17 |
AU2021291231A1 (en) | 2023-02-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR112022025653A2 (pt) | Vacina autoamplificante de rna sars-cov-2 | |
CY1122117T1 (el) | Ενεργοποιηση μιας ανοσοαποκρισης | |
BR112018013930A2 (pt) | vírus oncolítico, vírus que expressa três genes heterólogos, composição farmacêutica, vírus para o uso, produto de fabricação, método de tratamento de câncer e uso do vírus | |
BR112019007433A2 (pt) | sistemas de replicon de vírus recombinante e usos dos mesmos | |
EA201201025A1 (ru) | Молекулы нуклеиновых кислот гриппа и вакцины, изготовленные из них | |
CL2018000226A1 (es) | Mezcla de péptidos (divisional solicitud 201601405) | |
BR112017008165A2 (pt) | anticorpos de domínio único direcionados contra antígenos intracelulares | |
CY1114762T1 (el) | Εμβολιασμος με πολλαπλους κλαδους του ιου της γριπης η5 α | |
NO20054608L (no) | Influensavirusvaksine | |
BRPI0519705A2 (pt) | composiÇÕes, proteÍnas de fusço e mÉtodos de estimular uma resposta imune em um indivÍduo | |
CY1110793T1 (el) | Εμβολιο φυματιωσης με βελτιωμενη αποτελεσματικοτητα | |
EA200700849A1 (ru) | Первичная/бустерная противомалярийная вакцина | |
BR112012005713A2 (pt) | vacinas direcionadas a célula langerhans. | |
BRPI0418317A (pt) | vacina de aumento de crescimento à base de epitopo de neutralização | |
CY1124667T1 (el) | Τροποποιημενο rna που κωδικοποιει πολυπεπτιδια vegf-a, φαρμακοτεχνικες μορφες, και χρησεις που σχετιζονται με αυτα | |
BR112015005987A2 (pt) | vacina, métodos para induzir uma resposta imune contra um antígeno hbv, para proteção de um sujeito da infeção por hbv, para proteger o sujeito que foi diagnosticado com uma infecção por hbv, para induzir uma resposta imune contra um antígeno do hbv, para proteger um indivíduo da infecção pelo hbv, para proteger um indivíduo que foi diagnosticado com infecção pelo hbv, para proteger um indivíduo da infecção pelo hbv, para proteger um indivíduo que foi diagnosticado com infecção pelo hbv, para proteger um sujeito contra infecção por hbv e para proteger o sujeito que foi diagnosticado com uma infecção por hbv, molécula de ácido nucleico, e, proteína | |
NO20081043L (no) | Vaksine for fisk | |
BR112015013004A2 (pt) | molécula de ácido nucleico isolada, composição, vacina, métodos de tratamento de um indivíduo e de prevenção de um tumor, proteína, e, peptídeo | |
BR112022022937A2 (pt) | Proteínas de fusão estabilizadas de proteína de pico de coronavírus | |
CY1124707T1 (el) | Συνθεσεις και μεθοδοι για την επαγωγη ενισχυμενης ανοσοαποκρισης με χρηση φορεων ιων poxvirus (ευλογοϊων) | |
BR112015022582A2 (pt) | molécula de ácido nucleico, plasmídeo, vacina, e, uso de um plasmídeo | |
AR067830A1 (es) | Proteinas streptococcus inmunogenicas | |
MX2023000041A (es) | Composiciones y metodos para inducir una respuesta inmunitaria contra coronavirus. | |
BR112022022859A2 (pt) | Vacinas contra sars-cov-2 | |
ES2721159T3 (es) | Antígenos asociados a tumor independientes de MHC novedosos |